IDEAYA Biosciences: Buy Rating Reiterated as Precision Oncology Pipeline Advances and $62 Price Target Maintained
Complete. Here is the key summaryLifeSci Capital analyst Charles Zhu reiterated a Buy rating on IDEAYA Biosciences with a $62 price target. The recommendation is driven by the advancement of its precision oncology pipeline, specifically the initiation of IDE892 monotherapy expansion in MTAP-deleted cancers. Key factors include rapid dose cohort progression, strong drug profile, and multiple combination strategies, supported by a 4.7-year cash runway.
LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences today and set a price target of $62.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Charles Zhu has given his Buy rating due to a combination of factors that underscore IDEAYA’s advancing precision oncology pipeline and solid execution. He views the initiation of IDE892 monotherapy expansion in MTAP-deleted pancreatic and non-small cell lung cancers as a meaningful step, particularly given the rapid progression through dose cohorts and achievement of target drug exposure levels.
He also highlights IDE892’s differentiated profile, including strong MTA-selective PRMT5 activity, limited brain penetration to reduce CNS risk, and a favorable outlook on drug–drug interactions versus competing agents. In parallel, IDEAYA is pursuing multiple combination strategies, planning a pan-RAS regimen and future CDKN2A development, all supported by an estimated 4.7 years of cash runway, which in his view justifies maintaining the $62 price target and Buy recommendation.